WallStreetZenWallStreetZen

NASDAQ: ZNTL
Zentalis Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ZNTL

Based on 5 analysts offering 12 month price targets for Zentalis Pharmaceuticals Inc

Min Forecast
$2.20+60.58%
Avg Forecast
$6.04+340.88%
Max Forecast
$10.00+629.93%

Should I buy or sell ZNTL stock?

Based on 5 analysts offering ratings for Zentalis Pharmaceuticals Inc.

Buy
Strong Buy
1 analysts 20%
Buy
1 analysts 20%
Hold
3 analysts 60%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ZNTL's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ZNTL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ZNTL stock forecasts and price targets.

ZNTL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-28
lockedlocked$00.00+00.00%2025-03-27
lockedlocked$00.00+00.00%2025-01-30
lockedlocked$00.00+00.00%2025-01-28
lockedlocked$00.00+00.00%2024-11-15

1 of 1

Forecast return on equity

Is ZNTL forecast to generate an efficient return?

Company
-32.8%
Industry
146.26%
Market
80.85%
ZNTL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ZNTL forecast to generate an efficient return on assets?

Company
-25.7%
Industry
36.38%
ZNTL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ZNTL earnings per share forecast

What is ZNTL's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$2.52
Avg 2 year Forecast
-$1.98
Avg 3 year Forecast
-$2.18

ZNTL revenue forecast

What is ZNTL's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$169.1M
Avg 2 year Forecast
$27.8M
Avg 3 year Forecast
$97.5M

ZNTL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ZNTL$1.37$6.04+340.88%Buy
OBIO$2.53$15.00+492.89%Strong Buy
VXRT$0.43$2.00+370.59%Strong Buy
HLVX$1.93$2.00+3.63%Hold
MGNX$1.60$2.00+25.00%Hold
View Top Biotech Stocks

Zentalis Pharmaceuticals Stock Forecast FAQ

Is Zentalis Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ZNTL) stock is to Buy ZNTL stock.

Out of 5 analysts, 1 (20%) are recommending ZNTL as a Strong Buy, 1 (20%) are recommending ZNTL as a Buy, 3 (60%) are recommending ZNTL as a Hold, 0 (0%) are recommending ZNTL as a Sell, and 0 (0%) are recommending ZNTL as a Strong Sell.

If you're new to stock investing, here's how to buy Zentalis Pharmaceuticals stock.

What is ZNTL's earnings growth forecast for 2025-2027?

(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Zentalis Pharmaceuticals's earnings in 2025 is -$165,839,000.On average, 7 Wall Street analysts forecast ZNTL's earnings for 2025 to be -$181,273,790, with the lowest ZNTL earnings forecast at -$231,951,171, and the highest ZNTL earnings forecast at -$144,341,131. On average, 7 Wall Street analysts forecast ZNTL's earnings for 2026 to be -$142,186,786, with the lowest ZNTL earnings forecast at -$200,354,107, and the highest ZNTL earnings forecast at -$26,570,258.

In 2027, ZNTL is forecast to generate -$156,692,710 in earnings, with the lowest earnings forecast at -$187,428,036 and the highest earnings forecast at -$119,925,218.

What is ZNTL's revenue growth forecast for 2026-2028?

(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Zentalis Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ZNTL's revenue for 2026 to be $12,144,762,233, with the lowest ZNTL revenue forecast at $12,144,762,233, and the highest ZNTL revenue forecast at $12,144,762,233. On average, 4 Wall Street analysts forecast ZNTL's revenue for 2027 to be $1,997,437,095, with the lowest ZNTL revenue forecast at $1,127,440,676, and the highest ZNTL revenue forecast at $3,087,894,844.

In 2028, ZNTL is forecast to generate $7,000,903,915 in revenue, with the lowest revenue forecast at $3,279,631,570 and the highest revenue forecast at $9,249,322,230.

What is ZNTL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ZNTL) forecast ROA is -25.7%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is ZNTL's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ZNTL price target, the average ZNTL price target is $6.04, with the highest ZNTL stock price forecast at $10.00 and the lowest ZNTL stock price forecast at $2.20.

On average, Wall Street analysts predict that Zentalis Pharmaceuticals's share price could reach $6.04 by Mar 28, 2026. The average Zentalis Pharmaceuticals stock price prediction forecasts a potential upside of 340.88% from the current ZNTL share price of $1.37.

What is ZNTL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ZNTL) Zentalis Pharmaceuticals's current Earnings Per Share (EPS) is -$2.33. On average, analysts forecast that ZNTL's EPS will be -$2.52 for 2025, with the lowest EPS forecast at -$3.23, and the highest EPS forecast at -$2.01. On average, analysts forecast that ZNTL's EPS will be -$1.98 for 2026, with the lowest EPS forecast at -$2.79, and the highest EPS forecast at -$0.37. In 2027, ZNTL's EPS is forecast to hit -$2.18 (min: -$2.61, max: -$1.67).

What is ZNTL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ZNTL) forecast ROE is -32.8%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.